ArticleBMC gastroenterology2025
Low-molecular-weight heparin alleviates L-arginine-induced acute pancreatitis by modulating lipid metabolism and inflammatory responses in a rat model.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigates the therapeutic potential of low-molecular-weight heparin (LMWH) in acute pancreatitis (AP), focusing on its effects on lipid metabolism, inflammatory responses, and pancreatic tissue integrity. The study also explores the involvement of the PI3K/Akt pathway in mediating LMWH’s protective effects.
methodsA rat model of AP was induced using L-arginine, followed by treatment with low-dose (100 IU/kg) or high-dose (500 IU/kg) LMWH. Serum biomarkers such as amylase, lipase, Alanine Aminotransferase(ALT), Aspartate Aminotransferase (AST), Interleukin-1 beta (IL-1β), Tumor Necrosis Factor-alpha (TNF-α), and lipid profiles were quantified using ELISA, while histopathological changes were evaluated through hematoxylin and eosin (HE) staining. Ultrastructural changes were observed via electron microscopy. The expression levels of Phosphatidylinositol 3-Kinase (PI3K), Phosphorylated Akt (p-Akt), sterol regulatory element-binding protein-1c (SREBP-1c) and fatty acid synthase (FAS)were determined by Western blot and RT-qPCR analysis.
resultsLMWH treatment significantly reduced serum amylase and lipase levels, alleviated liver and kidney injury markers ALT, AST, Blood Urea Nitrogen (BUN), and Creatinine (CREA), and improved lipid profiles by lowering triglycerides (TG)and cholesterol (TC) while increasing HDL-C (P < 0.05). The levels of inflammatory cytokines IL-1β and TNF-α were significantly lower in the LMWH-treated groups compared to the AP group (P < 0.05). HE staining and electron microscopy revealed that LMWH preserved pancreatic tissue architecture and reduced acinar cell necrosis and mitochondrial damage. High-dose LMWH showed greater efficacy than low-dose treatment. LMWH downregulated the expression of lipid metabolism–related genes SREBP-1c and FAS, suggesting an inhibitory effect on lipogenesis. These effects might be driven by the activation of the PI3K/Akt signaling pathway.
conclusionLMWH ameliorates acute pancreatitis by mitigating pancreatic injury, suppressing inflammatory responses, and modulating lipid metabolism. These effects might be driven by the activation of the PI3K/Akt signaling pathway. LMWH holds promise as an adjunctive therapy for AP, warranting further exploration in clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.